This HTML5 document contains 51 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n13http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064165%3A_____%2F10%3A6831%21RIV11-MZ0-00064165/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n11http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n10http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n15http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n8http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064165%3A_____%2F10%3A6831%21RIV11-MZ0-00064165
rdf:type
skos:Concept n11:Vysledek
dcterms:description
The median age was 68 years, and the glomerular filtration rate (GFR) was 18 ml per minute per 1.73 m(2) of body-surface area. A total of 25 patients in the rituximab group (76%) and 9 patients in the control group (82%) had a sustained remission (P=0.68). Severe adverse events occurred in 14 patients in the rituximab group (42%) and 4 patients in the control group (36%) (P=0.77). Six of the 33 patients in the rituximab group (18%) and 2 of the 11 patients in the control group (18%) died (P=1.00). The median increase in the GFR between 0 and 12 months was 19 ml per minute in the rituximab group and 15 ml per minute in the control group (P=0.14). The median age was 68 years, and the glomerular filtration rate (GFR) was 18 ml per minute per 1.73 m(2) of body-surface area. A total of 25 patients in the rituximab group (76%) and 9 patients in the control group (82%) had a sustained remission (P=0.68). Severe adverse events occurred in 14 patients in the rituximab group (42%) and 4 patients in the control group (36%) (P=0.77). Six of the 33 patients in the rituximab group (18%) and 2 of the 11 patients in the control group (18%) died (P=1.00). The median increase in the GFR between 0 and 12 months was 19 ml per minute in the rituximab group and 15 ml per minute in the control group (P=0.14).
dcterms:title
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis
skos:prefLabel
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis
skos:notation
RIV/00064165:_____/10:6831!RIV11-MZ0-00064165
n3:aktivita
n6:V
n3:aktivity
V
n3:cisloPeriodika
3
n3:dodaniDat
n8:2011
n3:domaciTvurceVysledku
n12:5909627
n3:druhVysledku
n16:J
n3:duvernostUdaju
n7:S
n3:entitaPredkladatele
n13:predkladatel
n3:idSjednocenehoVysledku
285389
n3:idVysledku
RIV/00064165:_____/10:6831
n3:jazykVysledku
n14:eng
n3:klicovaSlova
Treatment with rituximab; cyclophosphamide; ANCA - associated renal vasculitis; remissin; reates of death
n3:klicoveSlovo
n10:remissin n10:reates%20of%20death n10:ANCA n10:Treatment%20with%20rituximab n10:cyclophosphamide
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[05871C1064CA]
n3:nazevZdroje
New England Journal of Medicine
n3:obor
n15:FE
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
14
n3:rokUplatneniVysledku
n8:2010
n3:svazekPeriodika
363
n3:tvurceVysledku
Luqmani, Raashid Walsh, Dorothy Savage, Carolina Westman, Kerstin Tervaert, Jan Williem Peh, Chem Au Morgan, Matew Hauser, Thomas Jayne, David Segelmark, Marten Paassen, Pieter Jones, Rachel Walsh, Michael Tesař, Vladimír
n3:wos
000279864200004
s:issn
0028-4793
s:numberOfPages
10